Why paediatric therapies could be Jagsonpal Pharmaceuticals’ next big growth driver in FY26

Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) is steadily strengthening its presence in the paediatric therapies segment, which analysts believe could become one of its most promising growth drivers in the coming quarters. While gynaecology and orthopaedics remain its core revenue pillars, the company’s increasing engagement with paediatricians and focus on essential child healthcare therapies signal a stronger push into this high-potential therapeutic category.

Currently, Jagsonpal Pharmaceuticals maintains regular contact with approximately 9,700 paediatricians out of 35,650 across India, representing nearly 27% coverage. Its paediatric product portfolio includes gut health probiotics, cough and cold formulations, and anti-diarrhoeal therapies, which continue to see consistent demand due to seasonal infection patterns and low preventive care penetration in semi-urban and rural markets.

How does Jagsonpal Pharmaceuticals’ paediatric portfolio align with its brand-driven business model?

The company’s paediatric expansion strategy aligns with its proven doctor-focused prescription model, which has driven its leadership in gynaecology and orthopaedics. Instead of relying on consumer-facing advertising, Jagsonpal Pharmaceuticals focuses on building strong prescription loyalty through frequent doctor engagement and targeted medical representative training.

This approach fits perfectly with its asset-light operating model. By outsourcing manufacturing to contract development and manufacturing organisations (CDMOs), Jagsonpal Pharmaceuticals avoids heavy capital expenditure while allocating resources to expanding its paediatric field force and enhancing brand-building initiatives. Analysts suggest that this cost-efficient structure could allow the company to scale its paediatric operations faster than peers with large in-house manufacturing setups.

Why is the Indian paediatric therapy market becoming a growth opportunity for branded generics?

India’s paediatric therapies market is expanding steadily due to demographic and healthcare trends. Gastrointestinal disorders, respiratory infections, and nutritional deficiencies remain common, driving demand for gut health probiotics, anti-diarrhoeals, and cough remedies. Seasonal outbreaks, especially during monsoon and winter months, ensure consistent prescription volumes for these therapies.

In addition, parental awareness of preventive healthcare is improving, and probiotic supplements for children are gaining traction in urban and semi-urban markets. Industry data suggests that the paediatric gut health segment could grow at a double-digit CAGR over the next five years, making it a lucrative area for branded generics players like Jagsonpal Pharmaceuticals.

Analysts also point out that paediatric categories face comparatively lower pricing pressure under India’s drug regulation framework, allowing branded companies to maintain healthy margins if they secure prescription loyalty early.

How does Jagsonpal Pharmaceuticals compare with competitors in paediatrics?

Compared to competitors such as Alkem Laboratories and Torrent Pharmaceuticals, which have broader paediatric portfolios including vaccines and specialised formulations, Jagsonpal Pharmaceuticals remains focused on high-frequency, branded generic therapies. While this limits its exposure to niche or high-value paediatric sub-segments, it positions the company firmly in categories with steady, repeat prescriptions.

Jagsonpal Pharmaceuticals’ 27% paediatrician coverage leaves significant room for expansion compared to its 90% penetration in gynaecology and 80% in orthopaedics. Analysts argue that increasing its doctor network reach to 50% or more could meaningfully boost paediatric sales and replicate its success in other therapeutic areas.

Competitors with strong hospital-based vaccine portfolios enjoy institutional procurement advantages, but Jagsonpal Pharmaceuticals’ nimble asset-light strategy makes it better positioned to target prescription-driven markets in tier-II and tier-III cities, where its medical representatives already have established relationships with doctors.

Can paediatric therapies become a significant revenue contributor in the near future?

Management has not disclosed segment-specific revenue contributions, but recent investor presentations highlight paediatrics as part of the company’s broader growth strategy. With four to six new products planned annually, analysts expect paediatric launches to focus on advanced probiotic formulations, new anti-diarrhoeal combinations, and improved cough and cold remedies.

The company’s robust cash position of ₹1,609 million gives it the financial flexibility to consider acquiring mid-sized paediatric brands, particularly in gut health and respiratory categories. Such acquisitions could accelerate its entry into higher-margin sub-segments and strengthen its brand recall among paediatricians.

While paediatrics may not overtake gynaecology or orthopaedics in revenue contribution immediately, expanding this segment will diversify Jagsonpal Pharmaceuticals’ portfolio, reducing reliance on a few core therapeutic categories and improving revenue resilience. If the company can replicate its gynaecology playbook—focused engagement, prescription loyalty, and niche product leadership—paediatrics could become a solid third growth pillar over the next two to three years.